Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with technologies for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.

Founded in 2001, the Company is dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (e.g. monoclonal antibodies (MAbs), growth factors, enzymes).

The Selexis SUREtechnology Platform™ improves the way cells are used in the discovery, development and manufacturing of recombinant protein drugs by providing key significant advantages over traditional approaches. The SUREtechnology Platform™ is based on Selexis Genetic Elements™ — novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The Selexis SUREtechnology Platform™ provides users a single platform that can be used for a wide range of applications from late R&D to biologics manufacturing including target discovery, cell-based assays, protein production for discovery and pre-clinical studies, diagnostics, bio-manufacturing of therapeutic proteins.

As of 4Q2011, Selexis has generated over 1,300 clonal cell lines being used in a variety of programs from discovery to late-stage clinical trials. More than 20 Selexis cell lines are in clinical trials and the Company anticipates several products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.